ArticleJournal of medical ultrasonics (2001)2026
Attenuation imaging and hepatorenal index composite score for the noninvasive assessment of hepatic steatosis in chronic liver disease: a prospective multicenter study.
Article in Journal of medical ultrasonics (2001), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe increasing prevalence of steatotic liver disease (SLD) underscores the need for reliable, noninvasive tools to assess hepatic steatosis. Existing methods, such as the controlled attenuation parameter (CAP) under ultrasound, have limitations in accuracy. This study aimed to examine whether combining attenuation imaging (AI) and hepatorenal index (HRI) measurements improves discrimination of steatosis in participants with chronic liver disease (CLD).
methodsThis multicenter prospective cohort study enrolled 121 participants with CLD from two centers during 2022-2023. All participants underwent liver biopsy and ultrasound examinations, including AI and HRI measurements using a Philips EPIQ system, and CAP assessment. An AI-HRI composite score was developed using logistic regression and evaluated against individual variables through receive operating characteristic analysis, category-free net reclassification improvement (cf-NRI), and integrated discrimination improvement (IDI). Internal validation was performed using bootstrap sampling.
resultsThe area under the curve values for discrimination for the AI-HRI composite score, AI, HRI, and CAP were 0.91, 0.87, 0.86, and 0.80, respectively. At a cutoff of -0.083, the sensitivity and specificity were 84.1% and 90.0%, respectively. The cf-NRI and IDI analyses demonstrated improved discrimination compared to other variables (p < 0.01). Bootstrap analysis confirmed the internal validity of the score (C-index: 0.90).
conclusionsThe AI-HRI composite score provides superior discrimination of steatosis in participants with CLD, potentially offering a more accurate and reliable tool for clinical assessment. These findings could facilitate improved management and early intervention in SLD.
Indexed as
Identifiers
42334696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.